Literature DB >> 22840209

Potential predictive biomarkers of obesity in Burmese cats.

Peter Lee1, Akihiro Mori, Marcia Coradini, Nobuko Mori, Fumi Sagara, Ichiro Yamamoto, Jacquie S Rand, Toshiro Arai.   

Abstract

Australian Burmese cats are predisposed to diabetes mellitus and, compared to other breeds, have delayed triglyceride clearance that may result in subtle changes within cells and tissues that trigger specific alterations in gene expression within peripheral blood leucocytes (PBLs). Expression of genes involved in energy metabolism (glucose-6-phosphate dehydrogenase and malate dehydrogenase), lipogenesis (ATP citrate lyase [ACL], fatty acid synthase [FAS] and sterol regulatory binding protein-1c [SREBP-1c]), and insulin signalling (insulin receptor substrates 1 and 2, and phosphatidylinositol-3 kinase), as well as cholesterol lipoprotein subfraction profiling were carried out on PBLs from lean Burmese cats and compared with similar profiles of age and gender matched lean and obese Australian domestic shorthaired cats (DSHs) in an attempt to identify possible biomarkers for assessing obesity. For the majority of the genes examined, the lean Burmese cats demonstrated similar PBL gene expression patterns as age and gender matched obese Australian DSH cats. Lean Burmese had increased expression of ACL and FAS, but not SREBP-1c, a main upstream regulator of lipid synthesis, suggesting possible aberrations in lipogenesis. Moreover, lean Burmese displayed a 3- to 4-fold increase in the very low density cholesterol fraction percentage, which was double that for obese DSH cats, indicating an increased degree of lipid dysregulation especially in relation to triglycerides. The findings suggest that Burmese cats may have a particular propensity for dysregulation in lipid metabolism.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22840209     DOI: 10.1016/j.tvjl.2012.06.027

Source DB:  PubMed          Journal:  Vet J        ISSN: 1090-0233            Impact factor:   2.688


  7 in total

Review 1.  The vital role of ATP citrate lyase in chronic diseases.

Authors:  Amrita Devi Khwairakpam; Kishore Banik; Sosmitha Girisa; Bano Shabnam; Mehdi Shakibaei; Lu Fan; Frank Arfuso; Javadi Monisha; Hong Wang; Xinliang Mao; Gautam Sethi; Ajaikumar B Kunnumakkara
Journal:  J Mol Med (Berl)       Date:  2019-12-19       Impact factor: 4.599

2.  Incidence of Diabetes Mellitus in Insured Swedish Cats in Relation to Age, Breed and Sex.

Authors:  M Öhlund; T Fall; B Ström Holst; H Hansson-Hamlin; B Bonnett; A Egenvall
Journal:  J Vet Intern Med       Date:  2015-07-14       Impact factor: 3.333

Review 3.  An individual approach to feline diabetes care: a case report and literature review.

Authors:  Moira S Lewitt; Emma Strage; David Church
Journal:  Acta Vet Scand       Date:  2016-10-20       Impact factor: 1.695

4.  Epidemiology of Diabetes Mellitus among 193,435 Cats Attending Primary-Care Veterinary Practices in England.

Authors:  D G O'Neill; R Gostelow; C Orme; D B Church; S J M Niessen; K Verheyen; D C Brodbelt
Journal:  J Vet Intern Med       Date:  2016-06-29       Impact factor: 3.333

5.  Decreased gene expressions of insulin signal molecules in canine hyperadrenocorticism.

Authors:  Satoshi Nozawa; Hitomi Oda; Ran Akiyama; Kaori Ueda; Kaori Saeki; Saori Shono; Natsuki Maruyama; Atsuki Murata; Hiroyuki Tazaki; Akihiro Mori; Yutaka Momota; Daigo Azakami; Toshinori Sako; Katsumi Ishioka
Journal:  J Vet Med Sci       Date:  2014-05-15       Impact factor: 1.267

6.  Mapping the genetic basis of diabetes mellitus in the Australian Burmese cat (Felis catus).

Authors:  Georgina Samaha; Claire M Wade; Julia Beatty; Leslie A Lyons; Linda M Fleeman; Bianca Haase
Journal:  Sci Rep       Date:  2020-11-05       Impact factor: 4.379

7.  A genome-wide association study identifies novel candidate genes for susceptibility to diabetes mellitus in non-obese cats.

Authors:  Yaiza Forcada; Mike Boursnell; Brian Catchpole; David B Church
Journal:  PLoS One       Date:  2021-12-07       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.